ReviewDiscover oncology2025
Role of interleukin-6 in resistance to tumor therapy.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- PD-L1 in Ovarian Cancer: Immune Evasion, Tumor-Intrinsic Signaling, and Chemoresistance.Cancer medicine · 2026Review
- The Red AlgaCurrent issues in molecular biology · 2026Article
- Microbiota and immune-related adverse events in cancer immunotherapy.Nature reviews. Cancer · 2026Review
- Curcumin and Cancer-Related Inflammation.Nutrients · 2026Review
- Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2026Review
- IL-6R blockade with tocilizumab disrupts pericyte- and tumor cell-driven IL-6/STAT3 signaling, enhancing docetaxel efficacy in ER+ breast cancer.bioRxiv : the preprint server for biology · 2026Article
- Tumor-associated macrophages in gastric cancer peritoneal metastasis: orchestrating immune evasion, niche remodeling, and therapeutic resistance.Frontiers in immunology · 2026Review
- Circulating cytokines as potential dynamic biomarkers of PD-1 blockade response and prognosis in non-small cell lung cancer.Frontiers in immunology · 2026Review
- Rearming mesenchymal stem cells with engineering strategies to combat cancer.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tumor therapy resistance presents a significant challenge in cancer treatment. Although substantial strides have been made in the domains of early diagnosis and therapeutic interventions within contemporary medicine, a considerable proportion of patients inevitably encounter resistance to treatment, culminating in therapeutic inefficacy and unfavorable clinical outcomes. Typically, such resistance is exhibited by tumor cells acquiring refractoriness to radiotherapy, chemotherapeutic drugs, targeted agents, and immunotherapeutic modalities. Accumulating data in recent years have increasingly implicated interleukin-6 (IL-6), a pivotal mediator of inflammatory responses, in not only the initiation, advancement, metastatic behavior, and immune escape of tumors but also in the promotion of resistance to various oncologic treatments. This review delineates current findings concerning the involvement of IL-6 in tumor-related therapeutic applications, with emphasis on its impact on prognosis, therapeutic resistance, and potential treatment pathways, aiming to facilitate the strategic integration of IL-6 in the refinement of cancer treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.